Artificial Sphincters for Urinary Incontinence — Cost, Top Hospitals & Success Rates | MyMedicPlus

The artificial urinary sphincter (AUS) is a surgically implanted hydraulic device designed to restore urinary continence in patients with severe intrinsic sphincter deficiency — most commonly men who experience stress urinary incontinence following radical prostatectomy for prostate cancer. It is considered the gold standard surgical treatment for this indication and has been in clinical use since the AMS 800 device received FDA approval in 1983.

The device consists of three components: an inflatable cuff that encircles the bulbar urethra (or bladder neck in women), a pressure-regulating balloon reservoir implanted in the space of Retzius or extraperitoneally, and a control pump placed in the scrotum (or labia majora in women). The system is filled with saline and operates at a pre-set pressure of 61–70 cmH2O, which maintains urethral occlusion at rest. To void, the patient squeezes the scrotal pump, which transfers fluid from the urethral cuff to the reservoir, opening the urethra and allowing voluntary urination. The cuff refills automatically within 60–120 seconds.

Implantation is performed via a perineal incision for cuff placement and a separate low abdominal or inguinal incision for the reservoir. The procedure takes approximately 60–90 minutes under spinal or general anaesthesia. The device is left deactivated for six to eight weeks post-operatively to allow tissue healing around the components. At the six-week visit, the surgeon activates the pump mechanism, and patients then learn to use the device correctly. The learning curve is typically short — most patients achieve satisfactory continence within the first few weeks of device activation.

Success rates for the AMS 800 are well-established: approximately 70–90% of men with post-prostatectomy incontinence achieve social continence (zero to one pad per day) following implantation, with high patient satisfaction rates maintained over 5–10 years.

The artificial urinary sphincter is primarily indicated for moderate to severe stress urinary incontinence (SUI) in men — specifically post-prostatectomy incontinence following radical prostatectomy (open, laparoscopic, or robotic-assisted) for prostate cancer. SUI after prostatectomy results from damage to the external urethral sphincter and its supporting structures during surgery, leaving the patient unable to control urination during physical activities such as coughing, sneezing, laughing, exercise, or positional changes. Men using more than two pads per day at 12 months post-prostatectomy who have failed pelvic floor physiotherapy are the primary candidate group.

Secondary indications include stress incontinence following transurethral resection of the prostate (TURP), pelvic radiation therapy (which damages sphincter nerves and vascularity), bladder neck surgery, and neurogenic sphincter incompetence due to spinal cord injury or spina bifida. In women, AUS implantation is a secondary option for intrinsic sphincter deficiency that has failed less invasive procedures such as mid-urethral slings. AUS is also used in children with congenital bladder outlet incompetence and neurogenic bladder associated with myelomeningocele.

Ideal candidates for artificial urinary sphincter implantation are men with moderate to severe post-prostatectomy incontinence — leaking more than two to three pads per day — who have completed at least 12 months post-surgery (to allow for spontaneous recovery), have had no improvement with structured pelvic floor muscle training for at least six months, and have no active urinary tract infection or urethral stricture. Pre-operative assessment includes urodynamic studies to confirm intrinsic sphincter deficiency, cystoscopy to evaluate the urethra and bladder, and baseline continence pad testing. Patients must have adequate manual dexterity to operate the scrotal pump and understand the device's function. Mental and physical capacity to self-catheterise if needed is also assessed.

Contraindications include active urinary tract infection, untreated urethral stricture, bladder outlet obstruction, detrusor overactivity (urgency incontinence) as the dominant symptom, prior urethral surgery or radiation without adequate tissue vascularity, poor tissue quality from prior pelvic radiation, and inability to operate the pump mechanism. Patients with recent prostate cancer recurrence or ongoing hormone therapy requiring urinary surveillance may need oncological clearance before proceeding. Morbid obesity increases operative difficulty. In irradiated patients, careful preoperative vascular assessment is essential as radiation-induced ischaemia significantly increases erosion risk.

The AMS 800 (Boston Scientific) remains the most widely implanted and studied AUS device worldwide, with the largest long-term outcome dataset. It is available in multiple cuff sizes (3.5 to 11 cm) to accommodate different urethral circumferences, and reservoir pressure ranges (51–60, 61–70, or 71–80 cmH2O) selected based on urodynamic parameters. The standard technique places the cuff at the bulbar urethra. In previously radiated patients or after prior AUS revision, transcorporal cuff placement (through the corpora cavernosa) provides increased tissue coverage and reduces erosion risk.

For women and patients requiring bladder neck cuff placement (as in neurogenic cases), the cuff is positioned at the bladder neck with modified surgical access. Alternative devices include the Zephyr Surgical Implants ZSI 375 and the FlowSecure device, which incorporate pressure-adjustment mechanisms and may offer advantages in specific patient groups — though these have smaller outcome datasets than the AMS 800. Male urethral slings (Advance, Virtue, ATOMS) are a less invasive alternative for mild to moderate post-prostatectomy incontinence (one to two pads per day), but are not appropriate for severe incontinence or irradiated fields where AUS is the standard of care. Periurethral bulking agent injections offer minimal benefit for sphincter deficiency in men and are generally not recommended as the primary treatment.

Clinical evidence consistently demonstrates that the AMS 800 achieves social continence (zero to one pad per day) in approximately 75–90% of men following radical prostatectomy-related incontinence. Patient satisfaction rates at five-year follow-up are approximately 85%, with significant improvements in quality of life measures including urinary-specific questionnaires (ICIQ-UI, AUA Symptom Score) and general health outcomes. The device provides continuous, reliable continence without the need for daily medication and allows normal voiding mechanics preserved over many years.

Long-term durability is well-established. The device survival rate (freedom from explantation) is approximately 75% at 10 years. Most revisions are performed for mechanical failure (15–20% at 10 years), cuff erosion (5–10%), or infection (1–2%), and revision surgery typically restores continence successfully. Unlike medical therapies, the AUS does not cause systemic side effects, does not require dose adjustment, and provides a consistent, mechanical form of continence restoration. Patients can also expect normal sexual function and voiding patterns, as the device mimics natural sphincter mechanisms.

Early complications (within 30 days) include infection (1–3%), urinary retention requiring catheterisation, wound haematoma, and rarely intraoperative urethral or bladder injury. Infection of the device, although uncommon, typically necessitates complete device removal and a three- to six-month waiting period before reimplantation. Urethral erosion — where the cuff causes pressure necrosis through the urethral wall — occurs in approximately 5–10% of cases overall and at higher rates (10–15%) in patients with prior pelvic radiation. Erosion also requires device removal and delayed reimplantation.

Mechanical failure, including fluid leaks from the system, pump malfunction, or reservoir over-pressurisation, affects approximately 15–20% of devices at 10 years. Cuff atrophy — progressive thinning of the periurethral tissue over time — can lead to recurrent incontinence without mechanical failure, necessitating revision with a smaller cuff or transcorporal placement. Device deactivation is necessary before any urethral instrumentation (catheterisation, cystoscopy) to prevent erosion, which requires patient education and medical alert documentation.

Post-operatively, patients are hospitalised for one to two days. A urethral catheter is left in situ for 24–48 hours. The device is left in the deactivated position for six to eight weeks to allow tissue healing and oedema resolution around the implant. During this period, patients continue to experience incontinence and use pads as before surgery. At the six-week post-operative appointment, the surgeon activates the device by compressing the deactivation button on the pump, and patients are taught the correct squeezing technique to operate the pump.

Follow-up appointments are scheduled at three months, six months, and twelve months after activation, with annual review thereafter. Urinary tract infection surveillance with urine culture is part of routine follow-up. Patients are educated to deactivate the device at night if they experience urethral discomfort, and must always inform any treating clinician — particularly urologists or emergency physicians — that they have an AUS implant before any urethral instrumentation is performed. Device components are MRI-conditional, and MRI at 1.5T or 3.0T is generally safe with appropriate precautions.

Artificial urinary sphincter implantation in the United States costs approximately USD 25,000–40,000 inclusive of device, surgical fees, anaesthesia, and hospitalisation. In the United Kingdom through private care, costs range from GBP 12,000–18,000. The high cost primarily reflects the implant device itself (USD 8,000–12,000 for the AMS 800 alone), plus the specialised surgical expertise required. In many healthcare systems, AUS implantation is covered by insurance or national health schemes for post-prostatectomy incontinence, but waiting times can be lengthy.

Patients seeking this procedure at internationally accredited hospitals abroad can save 50–70% of Western prices. At JCI-accredited hospitals in India (e.g., Apollo, Manipal, Fortis), the total cost including implant, surgery, and hospital stay is approximately USD 6,000–10,000. In Thailand and Turkey, comparable costs range from USD 8,000–14,000. All major hospitals use the AMS 800 device — the same product used in the US and UK — imported and certified for use. Patients are advised to confirm that the implanting surgeon has specific AUS training and a high-volume caseload before proceeding, as outcomes are significantly influenced by surgeon experience.

For mild to moderate post-prostatectomy incontinence (one to two pads per day), male urethral slings — particularly the Advance XP and Virtue slings — offer a less invasive alternative with success rates of 50–65% for mild cases, without the need for a pump mechanism. These require adequate sphincter remnant function and are not suitable for severely irradiated patients. Periurethral bulking agents (Bulkamid, Macroplastique) provide modest short-term benefit for mild sphincter deficiency but have limited durability and are rarely recommended as primary therapy in men.

Pelvic floor muscle training and bladder training, when commenced early after prostatectomy, remain the first-line treatment for post-prostatectomy incontinence and should be pursued for 12 months before surgical intervention is considered. Pharmacological options are limited — duloxetine is used in some countries for stress incontinence but has modest efficacy and significant side effects. Absorbent products remain a management strategy rather than a treatment. For neurogenic sphincter incompetence in children and adults with spinal cord injury, clean intermittent catheterisation combined with anticholinergic therapy may avoid surgical intervention, but AUS remains the definitive solution for severe intrinsic sphincter incompetence.